Please assess the completion status of the following clinical trial:

Trial Title: Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Consenting patients fulfilling the Poser's criteria for definite MS~2. Age 18-70~3. Male and female~4. EDSS rate 5.5-7.5 (moderate to high disability)~5. Failure to two lines of the currently available registered immunomodulatory treatments for MS. The lack of response to these treatments was determined by either an increase in EDSS or the appearance of at least two relapses of MS during the year prior to inclusion.~Exclusion Criteria:~1. Patients who were treated with cytotoxic medications during the last three months prior to the infusion.~2. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results.~3. Patients with active infections.~4. Patients with cognitive decline or inability to understand and sign the informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Repeated MSCs treatment in MS patients (Type: EXPERIMENTAL): Treatment with intrathecal and intravenous injection of autologous MSC (1 million cells per Kg of body weight)

Based on this trial design, predict the completion outcome and termination type (if applicable).